- Home
- RNXT vs SLGL Comparison
RNXT vs SLGL Comparison
Compare RNXT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- SLGL
- Stock Information
- Founded
- RNXT 2012
- SLGL 1997
- Country
- RNXT United States
- SLGL Israel
- Employees
- RNXT N/A
- SLGL N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- SLGL Health Care
- Exchange
- RNXT Nasdaq
- SLGL Nasdaq
- Market Cap
- RNXT 44.6M
- SLGL 19.3M
- IPO Year
- RNXT 2021
- SLGL 2018
- Fundamental
- Price
- RNXT $1.30
- SLGL $8.14
- Analyst Decision
- RNXT Strong Buy
- SLGL Buy
- Analyst Count
- RNXT 2
- SLGL 1
- Target Price
- RNXT $7.25
- SLGL $40.00
- AVG Volume (30 Days)
- RNXT 135.9K
- SLGL 25.4K
- Earning Date
- RNXT 08-12-2025
- SLGL 08-15-2025
- Dividend Yield
- RNXT N/A
- SLGL N/A
- EPS Growth
- RNXT N/A
- SLGL N/A
- EPS
- RNXT N/A
- SLGL N/A
- Revenue
- RNXT $240,000.00
- SLGL $12,103,000.00
- Revenue This Year
- RNXT $3,104.65
- SLGL N/A
- Revenue Next Year
- RNXT $301.89
- SLGL $31.17
- P/E Ratio
- RNXT N/A
- SLGL N/A
- Revenue Growth
- RNXT N/A
- SLGL 603.66
- 52 Week Low
- RNXT $0.75
- SLGL $3.34
- 52 Week High
- RNXT $1.69
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- RNXT 53.41
- SLGL 63.80
- Support Level
- RNXT $1.29
- SLGL $6.96
- Resistance Level
- RNXT $1.38
- SLGL $7.48
- Average True Range (ATR)
- RNXT 0.07
- SLGL 0.28
- MACD
- RNXT -0.01
- SLGL 0.07
- Stochastic Oscillator
- RNXT 48.39
- SLGL 95.88
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.